Evidence check: CYP1A2 in the context of sleep

The provided context does not contain direct evidence linking CYP1A2 genotype to sleep outcomes. CYP1A2 is primarily known for metabolizing caffeine; variants (e.g., rs762551) affect caffeine clearance. Fast metabolizers (C allele) break down caffeine more quickly, which could theoretically reduce caffeine's sleep-disrupting effects. Slow metabolizers (A allele) have higher caffeine levels and may be more sensitive to caffeine, potentially impairing sleep quality. However, these effects are indirect and heavily dependent on individual caffeine intake. Evidence for a direct association between CYP1A2 and sleep disorders is weak, mostly based on observational studies or mechanistic reasoning. No robust clinical trials support personalized sleep recommendations based solely on CYP1A2 genotype. Other factors such as chronotype, stress, sleep hygiene, and overall health are far more influential. Therefore, the utility of a DNA test for CYP1A2 in the context of sleep is limited. The evidence is rated as 'unclear'.